Identification of the first-in-class dual inhibitors of human DNA topoisomerase IIα and indoleamine-2,3-dioxygenase 1 (IDO 1) with strong anticancer properties-Reference-Cited by-同舟云学术

Identification of the first-in-class dual inhibitors of human DNA topoisomerase IIα and indoleamine-2,3-dioxygenase 1 (IDO 1) with strong anticancer properties

Published:2022-11-08 Issue:1 Volume:38 Page:192-202
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

Kaproń Barbara¹^ORCID,Płazińska Anita²,Płaziński Wojciech²³,Plech Tomasz⁴^ORCID

Affiliation:

1. Department of Clinical Genetics, Medical University of Lublin, Lublin, Poland

2. Department of Biopharmacy, Medical University of Lublin, Lublin, Poland

3. Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Cracow, Poland

4. Department of Pharmacology, Medical University of Lublin, Lublin, Poland

Funder

National Science Centre, Poland

IDO1/IDO2/TDO

statutory fund

Medical University of Lublin

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2022.2140420

Reference23 articles.

1. [accessed 23 May 2022] https://www.who.int/news-room/fact-sheets/detail/cancer

2. [accessed 23 May 2022] https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf

3. European cancer mortality predictions for the year 2022 with focus on ovarian cancer

4. [accessed 23 May 2022] https://www.nih.gov/news-events/news-releases/cancer-costs-projected-reachleast-158-billion-2020

5. Targeting DNA topoisomerase II in cancer chemotherapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and activity study of novel N,N-diphenylurea derivatives as IDO1 inhibitors;Frontiers in Chemistry;2023-06-20

2. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment;Cancers;2023-05-11

3. Thiosemicarbazide Derivatives Targeting Human TopoIIα and IDO-1 as Small-Molecule Drug Candidates for Breast Cancer Treatment;International Journal of Molecular Sciences;2023-03-18

4. Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression;Pharmacological Research;2023-01